Braun Stacey Associates’s Supernus Pharmaceuticals SUPN Stock Holding History

Braun Stacey Associates’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-14,459	Closed	-$507K	–	122
2019 Q1	$507K	Sell	14,459 -92,762	-87%	-$3.45M	0.03%	111
2018 Q4	$3.56M	Sell	107,221 -33,995	-24%	-$1.46M	0.28%	98
2018 Q3	$7.11M	Sell	141,216 -19,418	-12%	-$959K	0.45%	92
2018 Q2	$9.61M	Buy	160,634 +154,914	+2,708%	+$8.03M	0.65%	82
2018 Q1	$262K	Sell	5,720 -5,315	-48%	-$222K	0.02%	125
2017 Q4	$440K	Buy	+11,035	New	+$436K	0.03%	124

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

NPIC

Neumeier Poma Investment Counsel Carmel, California $1.21B AUM 70.48% 1-Year Est. Return

Braun Stacey Associates's SUPN Position: Q2 2019 in Review

Braun Stacey Associates sold out of Supernus Pharmaceuticals (SUPN) in Q2 2019, closing a stake of 14,459 shares — an estimated $507K sold.

Braun Stacey Associates first reported a position in SUPN in Q4 2017 and held it in 6 quarters. The position peaked at $9.61M in Q2 2018. 272 funds tracked by Wall St. Rank hold SUPN as of Q2 2019.

Braun Stacey Associates reported no remaining Supernus Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Braun Stacey Associates sold 14,459 Supernus Pharmaceuticals shares in Q2 2019, an estimated $507K.
Braun Stacey Associates first reported a position in Supernus Pharmaceuticals in Q4 2017 and held it in 6 quarters.
Braun Stacey Associates's Supernus Pharmaceuticals position peaked at $9.61M in Q2 2018.
272 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2019.

Based on Braun Stacey Associates's 13F filing for Q2 2019, filed 25 Jul 2019.